Dr. Hellmann on Nivolumab in Combination with Ipilimumab for Small Cell Lung Cancer

Matthew D. Hellmann, MD
Published: Monday, Jun 19, 2017



Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).

CheckMate-032 is a phase I/II study investigating patients with SCLC who were treated with or without ipilimumab, explains Hellmann. This study was conducted because outcomes and treatment options for patients with SCLC are poor.

A total of 150 patients with SCLC were designed to receive ipilimumab or nivolumab, states Hellmann. Since there were early signs of promising efficacy, nivolumab with or without ipilimumab was added to the NCCN guidelines.

This also prompted a randomized study where 250 patients were randomized to either nivolumab alone or nivolumab with ipilimumab, in order to confirm efficacy and determine potential biomarkers.
 


Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).

CheckMate-032 is a phase I/II study investigating patients with SCLC who were treated with or without ipilimumab, explains Hellmann. This study was conducted because outcomes and treatment options for patients with SCLC are poor.

A total of 150 patients with SCLC were designed to receive ipilimumab or nivolumab, states Hellmann. Since there were early signs of promising efficacy, nivolumab with or without ipilimumab was added to the NCCN guidelines.

This also prompted a randomized study where 250 patients were randomized to either nivolumab alone or nivolumab with ipilimumab, in order to confirm efficacy and determine potential biomarkers.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x